Risk of Deliveries Before Prices Are Determined and Prolonged Price Negotiations
First written in FY2018. 3 of 7 entries say "Restated". Latest entry: FY2023-Q2.
0 other companies' latest entry also says "Worsened".
- FY2023-Q2WorsenedAnnual report
「As responses to generic drug supply suspensions and shipment adjustments limited the time available for price negotiations with medical institutions, the company sought to offer prices commensurate with the value of each product and distribution costs.」
It states that responses to generic drug supply suspensions and shipment adjustments limited the time available for price negotiations with medical institutions, demonstrating the difficult negotiating environment. - FY2022MitigatedAnnual report
「The company sets prices for each product according to its value and seeks to sell at appropriate prices by operating a price-lock system under which only the head office is authorized to approve sales below the set price.」
To manage the risks of prolonged price negotiations and discrepancies in agreed prices, the company operates a system combining pricing controls with head-office approval. - FY2022-Q2WorsenedAnnual report
「In addition to the continuing impact of the COVID-19 pandemic on medical institutions since the previous fiscal year, quality problems and GMP violations at some generic drug manufacturers led to a succession of product recalls and shipment adjustments, resulting in extremely difficult price negotiations with medical institutions.」
It states that successive recalls and shipment adjustments caused by quality problems and GMP violations at generic drug manufacturers have made price negotiations with medical institutions "extremely difficult." - FY2022-Q1RestatedAnnual report
「This was due in part to the impact of the April 2021 drug price revision and continued difficult price negotiations with medical institutions」
It states that price negotiations with medical institutions remain difficult and reconfirms the risk of an impact on results from prolonged negotiations and other factors. - FY2020RestatedAnnual report
「If price negotiations take a long time or result in prices different from those initially expected, the performance of the Group may be affected.」
The impact on performance of delivery before prices are determined and prolonged price negotiations or differences in determined prices remains a risk. - FY2019RestatedAnnual report
「If price negotiations take a long time or result in prices different from those initially expected, the performance of the Group may be affected.」
The impact on performance of delivery before prices are determined and prolonged price negotiations or differences in determined prices remains a risk. - FY2018First statedAnnual report
「A distinctive trading practice has continued from the past in which pharmaceuticals are delivered to medical institutions and dispensing pharmacies before prices are determined, followed by price negotiations. If price negotiations take a long time or result in prices different from those initially expected, the performance of the Group may be affected.」
Delivery before prices are determined, recognition of sales based on reasonable estimates, and prolonged price negotiations and differences in determined prices are described as new risks affecting performance.